A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Andrew Yee, Elizabeth O'Donnell, Omar Nadeem, Garth Nelson, Tanya Wildes, Tondre Buck, Sascha Tuchman, Krishna Ghimire, Sarah Sinclair, Catherine Stewart, Paul Richardson, Saad Usmani, Noopur Raje
Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Mayo Clinic, Nebraska Medical Center, University of Nebraska Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, SUNY Upstate Medical University, Alliance Foundation Trials, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108439447
Cites:
Cited by:
Related to: